Cell therapy using UC-MSCs for patients with lupus

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the safety and effectiveness of umbilical cord-derived mesenchymal stem cells (UC-MSCs) in adults diagnosed with systemic lupus erythematosus (SLE). Participants will receive a single dose of UC-MSCs alongside their standard treatment and will undergo regular assessments, including blood and urine tests, to monitor kidney function and disease activity. The study aims to determine if UC-MSCs can improve kidney health and reduce disease symptoms while ensuring patient safety through monitoring for adverse effects.

Why it matters

Who can join: the full rules

Inclusion Criteria

1. Age 18-75 years at the time of screening
2. Diagnosis of systemic lupus erythematosus (SLE), meeting at least 4 of the 11 criteria included in the American College of Rheumatology (ACR) Classification Criteria and/or 4 of the 17 criteria (with at least one of those being clinical and at least one being immunologic) included in the Systemic Lupus International Collaborating Clinics (SLICC) Criteria, at the screening visit.
3. Must have a positive ANA (≥1:160 titer) or positive anti-dsDNA antibody test within 6 months of the screening visit
4. An eGFR of ≥ 30 mL/min/1.73 m2 in the screening period
5. Prior SLE background therapy with at least one non-biologic medication (e.g. immunosuppressant and/or antimalarial), not including corticosteroids, is required for ≥ 12 weeks before the screening visit.
6. SLEDAI-2K ≥6 at the time of screening
7. Participant able and willing to provide written informed consent
8. Must be able and willing to adhere to the study visit schedule and other protocol requirements.

Exclusion Criteria

1. History of any non-systemic lupus erythematosus (non-SLE) disease that required treatment with oral or parenteral corticosteroids for more than a total of 2 weeks within the 12 weeks preceding the screening visit.
2. History of dialysis within 12 months prior to the screening visit or expected need for renal replacement therapy (dialysis or renal transplant) within a six-month period after enrollment.
3. Use of prednisone \>0.5 mg/kg/day (or equivalent corticosteroid) in the 4 weeks prior to the screening visit.
4. Any change or addition to a non-biologic immunosuppressant and/ or antimalarial regimen (not including corticosteroids) ≤ 12 weeks prior to the Screening visit.
5. Treatment with an interventional agent within the washout time of 90 days or 5 half-lives prior to Baseline (Day 0), whichever is longer.
6. Receipt of any commercially available biologic agent within the washout period described above prior to Baseline (Day 0).
7. Receipt of prior MSC therapy within the washout time of 52 weeks prior to Baseline (Day 0).
8. Previous treatment with any type of cellular therapy e.g., Tregs or CAR-T cells, with the exception of previous MSCs.
9. Major surgery within 90 days prior to Baseline (Day 0) or major surgery planned during the study period
10. Confirmed positive test for active hepatitis B, hepatitis C, human immunodeficiency virus (HIV) or tuberculosis (TB).
11. Any active infection that has not been adequately treated or completely resolved prior to Baseline (Day 0).
12. History of cancer, apart from adequately treated squamous or basal cell carcinoma of the skin, or cervical carcinoma in situ
13. Pregnant or breast-feeding women and women with intention to become pregnant/to breast-feed during the duration of the trial.
14. Women and men who do not agree to use a medically acceptable form of contraception for the duration of the trial.
15. Any other comorbidity which may render the participant unfit for study participation according to the investigator's judgement.
16. Any other medical condition, which in the opinion of the investigator, may impact the quality or interpretation of the data obtained from the study.

Where it's running

• Medical University of South Carolina
  Charleston, South Carolina, United States Recruiting

Study contacts

• Study coordinator: Nadya Lisovoder, MD
• Email: nadyal@galilee-cbr.com
• Phone: +972524753435

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• ONT01 for Lupus Nephritis and Systemic Lupus Erythematosus

  We will test whether ONT01 is safe and helps adults with lupus nephritis or active SLE when added to standard medicines like mycophenolate.

  Recruiting Early Phase 1 Hospital for Special Surgery, New York · New York, New York · NCT07107659

• CART19 treatment for lupus in young patients

  This study is testing a new treatment called CART19 to see if it can help young people aged 12-29 with tough-to-treat lupus feel better and improve their health.

  Recruiting Phase 1/2 Children's Hospital of Philadelphia · Philadelphia, Pennsylvania · NCT06839976

• Mosunetuzumab for people with systemic lupus erythematosus

  This study tests mosunetuzumab in people with systemic lupus erythematosus, with or without active lupus nephritis.

  Recruiting at 24 sites Phase 2 Hoffmann-La Roche · CABA, Buenos Aires and 23 other locations · NCT07598396

• Combination treatment for autoimmune disorders using specialized cells and chemotherapy

  This study is testing a new combination of specialized cells and chemotherapy to see if it can help people with autoimmune disorders like systemic sclerosis and lupus feel better.

  Recruiting at 2 sites Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas and 1 other locations · NCT06434363

• Effects of anifrolumab on arterial inflammation in SLE patients

  This study tests whether anifrolumab can reduce blood vessel inflammation in people with active systemic lupus erythematosus.

  Recruiting University of Cambridge · Cambridge, Cambridgeshire · NCT07913919

• Predicting SLE Flares with Patient Reports and Machine Learning

  Aims to test a low-cost, patient-reported outcome–based machine learning tool to see if it can detect lupus flares early and support care, especially in settings with limited resources.

  Recruiting Sohag University · Sohag, Nasr City · NCT07890662

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.